A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections
Sarah C. Vick, Marie Frutoso, Florian Mair, A Konecny, Evan Greene, Caitlin R. Wolf, Jennifer K. Logue, Nicholas Franko, Jim Boonyaratanakornkit, Raphaël Gottardo, Joshua T. Schiffer, Helen Y. Chu, Martin Prlic, Jennifer M. Lund
Abstract
are considered for therapy to combat the severe inflammation seen in COVID-19 patients. Likewise, having defined the overlapping immune landscapes in SARS-CoV-2, existing knowledge of flu and RSV infections could be leveraged to identify common treatment strategies.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Immune systemSignature (topology)2019-20 coronavirus outbreakRespiratory systemSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyBetacoronavirusCoronavirus InfectionsVirologyComputational biologyImmunologyMedicineEvolutionary biologyPathologyDiseaseMathematicsOutbreakInfectious disease (medical specialty)AnatomyGeometrySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19